Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunocore Holdings ( (IMCR) ) has issued an announcement.
On January 9, 2026, Immunocore outlined its 2026 strategic priorities, centered on expanding its melanoma franchise around KIMMTRAK through greater penetration in U.S. community oncology centers and global markets, and advancing three registrational Phase 3 melanoma trials, including TEBE-AM in previously treated cutaneous melanoma, ATOM in adjuvant uveal melanoma and PRISM-MEL-301 in first-line cutaneous melanoma. The company plans multiple 2026 data readouts across its pipeline, including Phase 1/2 results from PRAME bispecific candidates brenetafusp and IMC-P115C in ovarian, lung and other solid tumors, additional Phase 1 HIV data, and initiation and regulatory steps for two autoimmune programs in type 1 diabetes and atopic dermatitis, supported by a preliminary unaudited year-end 2025 cash position of about $864 million, which underscores its capacity to fund clinical development and reinforces its positioning as a growing player in oncology and adjacent disease areas.
The most recent analyst rating on (IMCR) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Immunocore Holdings stock, see the IMCR Stock Forecast page.
Spark’s Take on IMCR Stock
According to Spark, TipRanks’ AI Analyst, IMCR is a Neutral.
Immunocore Holdings’ overall stock score is primarily influenced by its strong technical indicators, which suggest a positive market trend. However, financial performance is hindered by ongoing profitability challenges and weak cash flow generation. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on IMCR stock, click here.
More about Immunocore Holdings
Immunocore Holdings plc is a commercial-stage biotechnology company specializing in immunomodulating medicines that harness engineered T cell receptor (TCR) technology, including its ImmTAC platform, to treat cancer, infectious diseases and autoimmune disorders. Its lead commercial product is KIMMTRAK (tebentafusp), currently the standard of care for HLA-A*02:01-positive patients with metastatic uveal melanoma, and the company is expanding its pipeline across melanoma, other solid tumors, HIV and autoimmune indications.
Average Trading Volume: 312,059
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.7B
See more data about IMCR stock on TipRanks’ Stock Analysis page.